ImpediMed Limited (ASX:IPD)

Australia flag Australia · Delayed Price · Currency is AUD
0.0140
-0.0010 (-6.67%)
Apr 29, 2026, 3:52 PM AEST
-61.11%
Market Cap 30.58M
Revenue (ttm) 14.23M
Net Income (ttm) -24.37M
Shares Out 2.04B
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,031,098
Average Volume 4,019,267
Open 0.0140
Previous Close 0.0150
Day's Range 0.0140 - 0.0140
52-Week Range 0.0130 - 0.0590
Beta 1.27
RSI 44.69
Earnings Date May 1, 2026

About ImpediMed

ImpediMed Limited, a medical technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) technology medical devices and software services in Australia, Europe, the United States, and internationally. The company offers SOZO, a noninvasive BIS device for the clinical assessment of lymphedema, which uses bioimpedance measurements to assess fluid levels and tissue composition; L-Dex analysis for lymphedema; BodyComp Analysis, a point-of-care body composition analysis; and HF-Dex analysis for point-of-care heart failure fl... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 1999
Employees 77
Stock Exchange Australian Securities Exchange
Ticker Symbol IPD
Full Company Profile

Financial Performance

In fiscal year 2025, ImpediMed's revenue was 12.72 million, an increase of 23.31% compared to the previous year's 10.32 million. Losses were -23.24 million, 17.4% more than in 2024.

Financial Statements

News

There is no news available yet.